'psychedelic drugs,' developed a 'video-methodology' for the study of psychopathology in psychopharmacology, and explored the effect of culture on the manifestations of psychiatric disorders. Then, in 1968, he was appointed Chief of the new Clinical Research Branch (CRB) of the Institute with the mission to stimulate research on the causes and treatment of schizophrenia and affective disorders. A key event during his tenure at CRB, and a turning point in his research, was the 1969 Williamsburg Conference that highlighted neurochemical theories about the pathogenesis of depression and brought to attention that progress in depression research would require the identification of better clinical end points and the development of suitable clinical methodology for testing relevant biochemical hypotheses. Launching soon after, a Collaborative Program
. During this period, he was also the Principal Investigator for NIMH funded research on the Psychobiology of Depression. He continued with his research well into the second decade of the twentyfirst century at the University of Texas Health Sciences Center in San Antonio.
Dr. Katz's contributions are crowned with the publication of two monographs in the last three years of his life in which he shows that deconstructing the diagnosis of depression, uncovering its dimensional structure and developing a methodology that allows the measuring of drug-induced changes on the independent dimensions that comprise it could open up a new perspective in the clinical development of drugs for the treatment of depression (Katz, 2013 (Katz, , 2016 . Marty Katz is survived by his wife, Barbara Gelb Katz, two children, Nancy and Pete, and two grandchildren. He will be dearly missed by his family, friends, and the neuropsychopharmacology community at large.
